In the trials, omalizumab and multi-allergen oral immunotherapy showed alike efficacy in protecting against food allergies, ...

ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented data demonstrating that switching to an integrase inhibitor-based antiretroviral regimen increased ...

Scientists have discovered a strategy to fight back against norovirus, a leading cause of gastroenteritis worldwide. Their new study identifies powerful antibodies capable of neutralizing a wide range ...

LOS ANGELES, March 12, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials Network focused on HIV and other infectious diseases, recently presented data demonstrating that tecovirimat did not ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from the HPTN 094 (“INTEGRA”) study at the 2025 ...

To learn more, please visit www.reprievetrial.org.

Eron, M.D., University of North Carolina ... It is sponsored by the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID, which also funds ACTG) under ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a ...

Vaccines. Fluoride. Autism. Communications involving these and 20 other “controversial, high profile, or sensitive” topics ...

Alpha-gal syndrome (AGS) is a severe tick-vectored food allergy caused by sensitivity to the galactose-alpha-1,3-galactose ...